메뉴 건너뛰기




Volumn 28, Issue 12, 2012, Pages 1921-1931

Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: Results of a prospective, investigator-blinded, randomized study

Author keywords

Ceftazidime resistant; Microbiological response; Uropathogens

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; CEFOTAXIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; IMIPENEM; NLX 104; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG;

EID: 84870399321     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.748653     Document Type: Article
Times cited : (204)

References (27)
  • 1
    • 78650106014 scopus 로고    scopus 로고
    • The epidemiology of urinary tract infections
    • Foxman B. The epidemiology of urinary tract infections. Nature Rev Urol 2010;7:653-60
    • (2010) Nature Rev Urol , vol.7 , pp. 653-660
    • Foxman, B.1
  • 2
    • 79952199427 scopus 로고    scopus 로고
    • Management of complicated urinary tract infections in the era of antimicrobial resistance
    • Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2010;122:7-15
    • (2010) Postgrad Med , vol.122 , pp. 7-15
    • Bader, M.S.1    Hawboldt, J.2    Brooks, A.3
  • 3
    • 36448971944 scopus 로고    scopus 로고
    • Complicated urinary tract infections
    • Neal Jr DE. Complicated urinary tract infections. Urol Clin N Am 2008;35:13-22
    • (2008) Urol Clin N Am , vol.35 , pp. 13-22
    • Neal Jr., D.E.1
  • 4
    • 33746766906 scopus 로고    scopus 로고
    • Urinary-catheter-associated infections in the elderly
    • Kunin CM. Urinary-catheter-associated infections in the elderly. Int J Antimicrob Agents 2006;28(Suppl 1):S78-81
    • (2006) Int J Antimicrob Agents , vol.28 , Issue.SUPPL. 1
    • Kunin, C.M.1
  • 5
    • 70149090868 scopus 로고    scopus 로고
    • A multinational survey of risk factors for infection with extended-spectrum jß-lactamase-producing Enterobacteriaceae in nonhospitalized patients
    • Ben-Ami R, Rodríguz-Bano J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum jß-lactamase- producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682-90
    • (2009) Clin Infect Dis , vol.49 , pp. 682-690
    • Ben-Ami, R.1    Rodríguz-Bano, J.2    Arslan, H.3
  • 6
    • 77249104101 scopus 로고    scopus 로고
    • Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: Changing epidemiology and drug treatment choices
    • Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010;70:313-33
    • (2010) Drugs , vol.70 , pp. 313-333
    • Pitout, J.D.1
  • 7
    • 62749195559 scopus 로고    scopus 로고
    • The real threat of Klebsiella pneumoniae carbapenemase producing bacteria
    • Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase producing bacteria. Lancet Infect Dis 2009;9:228-36
    • (2009) Lancet Infect Dis , vol.9 , pp. 228-236
    • Nordmann, P.1    Cuzon, G.2    Naas, T.3
  • 8
    • 79952420498 scopus 로고    scopus 로고
    • Current concepts in antimicrobial therapy against resistant Gram-negative organisms: Extended-spectrum jß-lactamase-produ-cing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa
    • Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: Extended-spectrum jß-lactamase-produ- cing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011; 86:250-9
    • (2011) Mayo Clin Proc , vol.86 , pp. 250-259
    • Kanj, S.S.1    Kanafani, Z.A.2
  • 9
    • 77955560486 scopus 로고    scopus 로고
    • Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens
    • Pfeifer Y, CullikA, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010;300:371-9
    • (2010) Int J Med Microbiol , vol.300 , pp. 371-379
    • Pfeifer, Y.1    Cullik, A.2    Witte, W.3
  • 10
    • 79957581336 scopus 로고    scopus 로고
    • Status report on carbapenemases: Challenge and prospects
    • Patel G, Bonomo RA. Status report on carbapenemases: challenge and prospects. Expert Rev Anti Infect Ther 2011;9:555-70
    • (2011) Expert Rev Anti Infect Ther , vol.9 , pp. 555-570
    • Patel, G.1    Bonomo, R.A.2
  • 11
    • 78650883759 scopus 로고    scopus 로고
    • Emergence of Klebsiella pneumonia carbapenemase-producing bacteria
    • Arnold RS, Thom KA, Sharma S, et al. Emergence of Klebsiella pneumonia carbapenemase-producing bacteria. South Med J 2011;104:40-5
    • (2011) South Med J , vol.104 , pp. 40-45
    • Arnold, R.S.1    Thom, K.A.2    Sharma, S.3
  • 13
    • 54549112247 scopus 로고    scopus 로고
    • NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases
    • Livermore DM, Mushtaq S, Warner M, et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother 2008;62:1053-6
    • (2008) J Antimicrob Chemother , vol.62 , pp. 1053-1056
    • Livermore, D.M.1    Mushtaq, S.2    Warner, M.3
  • 14
    • 67749143907 scopus 로고    scopus 로고
    • In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases
    • Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009;53:3599-601
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 3599-3601
    • Endimiani, A.1    Choudhary, Y.2    Bonomo, R.A.3
  • 15
    • 67650718178 scopus 로고    scopus 로고
    • In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
    • Stachyra T, Levasseur P, Péchereau MC, et al. In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009;64:326-9
    • (2009) J Antimicrob Chemother , vol.64 , pp. 326-329
    • Stachyra, T.1    Levasseur, P.2    Péchereau, M.C.3
  • 16
    • 79955537450 scopus 로고    scopus 로고
    • Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases
    • Lagacé-Weins PR, Tailor F, Simner P, et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 2011;55:2434-7
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 2434-2437
    • Lagacé-Weins, P.R.1    Tailor, F.2    Simner, P.3
  • 17
    • 78650636489 scopus 로고    scopus 로고
    • Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae
    • Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390-4
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 390-394
    • Livermore, D.M.1    Mushtaq, S.2    Warner, M.3
  • 19
    • 33646696219 scopus 로고    scopus 로고
    • Clinical and Laboratory Standards Institute Twentieth informational supplement. M100-S20, Wayne, PA, USA
    • Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement. M100-S20, Wayne, PA, USA, 2010
    • (2010) Performance Standards for Antimicrobial Susceptibility Testing
  • 20
    • 84856228220 scopus 로고    scopus 로고
    • Epidemiology, treatment and prevention of healthcare-associated urinary tract infections
    • Wagenlehner FME, Cek M, Naber KG, et al. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 2012;30:59-67
    • (2012) World J Urol , vol.30 , pp. 59-67
    • Wagenlehner, F.M.E.1    Cek, M.2    Naber, K.G.3
  • 21
    • 70349134718 scopus 로고    scopus 로고
    • Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis
    • Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009;53:3782-92
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 3782-3792
    • Naber, K.G.1    Llorens, L.2    Kaniga, K.3
  • 22
    • 23244454191 scopus 로고    scopus 로고
    • Double-blind, controlled study to evaluate safety and efficacy of doripenem and meropenem in patients with complicated urinary tract infection
    • [Article in Japanese.] Jpn
    • Kamidono S, Arakawa S, Hirose T, et al. [Double-blind, controlled study to evaluate safety and efficacy of doripenem and meropenem in patients with complicated urinary tract infection.] [Article in Japanese.] Jpn J Chemother 2005;53(Suppl 1):244-59
    • (2005) J Chemother , vol.53 , Issue.SUPPL. 1 , pp. 244-259
    • Kamidono, S.1    Arakawa, S.2    Hirose, T.3
  • 23
    • 0028589111 scopus 로고
    • Piperacillin/tazobactam in complicated urinary tract infections
    • Nowé P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med 1994;20(Suppl 3):S39-42
    • (1994) Intensive Care Med , vol.20 , Issue.SUPPL. 3
    • Nowé, P.1
  • 24
    • 0029872212 scopus 로고    scopus 로고
    • Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: An open non-comparative and multicentered trial
    • Sifuentes-Osornio J, Jakob E, Clara L, et al. Piperacillin/tazobactam in the treatment of hospitalized patients with urinary tract infections: an open non-comparative and multicentered trial. J Chemother 1996;8:122-9
    • (1996) J Chemother , vol.8 , pp. 122-129
    • Sifuentes-Osornio, J.1    Jakob, E.2    Clara, L.3
  • 25
    • 0026768843 scopus 로고
    • Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy
    • Buckley MM, Brogden RN, Barradell LB, et al. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992;44:408-44
    • (1992) Drugs , vol.44 , pp. 408-444
    • Buckley, M.M.1    Brogden, R.N.2    Barradell, L.B.3
  • 26
    • 0036583850 scopus 로고    scopus 로고
    • Effectiveness of Imipenemcilastatin (Tienam MSD) in Treating Complicated Infections in Urology
    • [Russian.] May-June
    • Derevianko II, Nefedova LA, Lavrinova LN. [Effectiveness of imipenem/cilastatin (Tienam, MSD) in treating complicated infections in urology.] [Russian.] Urologiia 2002 May-June;(3):21-5
    • (2002) Urologiia , Issue.3 , pp. 21-25
    • Derevianko, I.I.1    Nefedova, L.A.2    Lavrinova, L.N.3
  • 27
    • 0029031384 scopus 로고
    • The renal membrane dipeptidase (dehydropepetidase I) inhibitor, cilastatin, inhibits the bacterial metallo-6-lactamase enzyme CphA
    • Keynan S, Hooper NM, Felici A, et al. The renal membrane dipeptidase (dehydropepetidase I) inhibitor, cilastatin, inhibits the bacterial metallo-6-lactamase enzyme CphA. Antimicrob Agents Chemother 1995;39:1629-31
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 1629-1631
    • Keynan, S.1    Hooper, N.M.2    Felici, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.